Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1680
    +0.0023 (+0.20%)
     
  • GBP/USD

    1.2493
    -0.0018 (-0.14%)
     
  • Bitcoin GBP

    51,166.93
    -738.51 (-1.42%)
     
  • CMC Crypto 200

    1,332.32
    -64.22 (-4.44%)
     
  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     
  • DOW

    38,239.66
    +153.86 (+0.40%)
     
  • CRUDE OIL

    83.64
    +0.07 (+0.08%)
     
  • GOLD FUTURES

    2,348.50
    +6.00 (+0.26%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Johnson & Johnson’s Acclarent Aera Balloon Dilation System

Johnson & Johnson’s Acclarent Aera Balloon Dilation System

Acclarent received FDA approval for its Acclarent Aera Balloon Dilation System for the treatment of ETD (eustachian tube dysfunction) in September 2016. For details, read Inside Johnson & Johnson’s Latest US Medical Device Launch. On February 27, 2018, Johnson & Johnson’s subsidiary Acclarent announced that the company received FDA approval for the expanded indication for Acclarent Aera.